Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "established-brands"

12 News Found

Sun Pharma eyes biosimilars-led growth, Organon deal to build $12.4 billion global platform
News | April 28, 2026

Sun Pharma eyes biosimilars-led growth, Organon deal to build $12.4 billion global platform

On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms


Sun Pharma to acquire Organon in $11.75 billion all-cash deal
News | April 27, 2026

Sun Pharma to acquire Organon in $11.75 billion all-cash deal

Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally


Zyax Chem takes 26% stake in Gaymed Labs
News | April 22, 2026

Zyax Chem takes 26% stake in Gaymed Labs

Targets high-growth eye care expansion push


Viatris sells stake in Biocon Biologics for $815 million, regains global Biosimilars access
News | December 09, 2025

Viatris sells stake in Biocon Biologics for $815 million, regains global Biosimilars access

Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares


Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India
News | September 16, 2025

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India

Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB


Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India
Supply Chain | March 27, 2024

Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India

Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium


Dr. Reddy's to acquire cardiovascular brand Cidmus in India
News | April 01, 2022

Dr. Reddy's to acquire cardiovascular brand Cidmus in India

The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction


Novartis India enters sales and distribution agreement with Dr. Reddy’s
News | February 12, 2022

Novartis India enters sales and distribution agreement with Dr. Reddy’s

Dr. Reddy’s to promote and distribute select Novartis products including the Voveran range, the Calcium range and Methergine in India